Changes in Hong Kong stocks | Peijia Medical-B (09996) rose more than 6% Taurus NXT system registration application accepted, Chairman of the Board began increasing its holdings this month

The Zhitong Finance App learned that Peijia Medical-B (09996) rose more than 6%. As of press release, it had risen 6.32% to HK$5.89, with a turnover of HK$1,989,500.

According to the news, on the evening of December 7, Peijia Medical issued an announcement stating that recently, the company received an acceptance notice from the State Drug Administration of the People's Republic of China confirming acceptance of the registration application for the TaurusNxT® “non-formaldehyde crosslinked” dry valve transcatheter aortic valve replacement (“TAVR”) system. TaurusNXT® is a third-generation TAVR system developed in-house by the company. It uses patented non-formaldehyde biological tissue crosslinking technology, which aims to improve the durability and biocompatibility of artificial aortic valves.

In addition, Peijia Healthcare announced that Dr. Zhang Yi, the executive director, CEO and chairman of the company's board of directors, began purchasing company shares on the open market on December 1, 2025 through the company he controls. The total cost of increased shareholding is expected to be no more than HK$15 million. According to Dr. Zhang, the increase in shareholding reflects its recognition of the company's intrinsic value and its firm confidence in the company's development prospects and growth potential.